- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00621244
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
16. december 2020 opdateret af: Novartis Pharmaceuticals
A Phase IA/II, Two-arm, Multi-center, Open-label, Dose-escalation Study of LBH589 Administered Orally Via Different Dosing Schedules in Adult Patients With Advanced Hematological Malignancies
This study evaluated safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies
Studieoversigt
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
175
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Victoria
-
Parkville, Victoria, Australien, 3002
- Novartis Investigative Site
-
Prahran, Victoria, Australien, 3181
- Novartis Investigative Site
-
-
-
-
Georgia
-
Augusta, Georgia, Forenede Stater, 30912
- Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Dana Farber Cancer Institute
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- MD Anderson Cancer Center/University of Texas
-
-
-
-
-
Frankfurt/M, Tyskland, 60590
- Novartis Investigative Site
-
Mainz, Tyskland, 55131
- Novartis Investigative Site
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion criteria:
- Adult patients (≥18 years old) with advanced hematological malignancies who relapsed after or are refractory to standard therapy, or for which no standard therapy existed; or, were considered inappropriate candidates for standard therapy
- World Health Organization (WHO) performance status ≤ 2
- Patients who met protocol-specified hematologic and non-hematologic laboratory values
- Patients with adequate liver and renal function
Exclusion criteria:
- Concurrent brain metastases or leukemic infiltration of the cerebrospinal fluid
- Peripheral neuropathy ≥ CTCAE grade 2
- Unresolved diarrhea ≥ CTCAE grade 2
- Concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study, including impaired heart function or clinically significant heart disease, and impaired gastrointestinal function or disease that significantly altered aborption of LBH589
- Female patients who were pregnant or breast feeding
- Patients who were unwilling to use an effective method of birth control
- Patients who took medications specified by the protocol as prohibited for administration in combination with LBH589
- Patients with another primary malignancy that required active intervention or were clinically significant
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Arm 1, Group X
|
|
Eksperimentel: Arm 1, Group Y
|
|
Eksperimentel: Arm 2, Group X
|
|
Eksperimentel: Arm 2, Group Y
Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week, as part of a 28-day treatment cycle.
Group Y is a sub-arm, based on disease indication.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of Participants DLT in Arm 1 in Dose Escalation Phase
Tidsramme: Cycle 1 (28-day treatment cycle)
|
Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for consecutive dosing schedule (MWF weekly).
A 3-parameter version of a Bayesian logistic regression model with overdose control (Babb, Rogatko, and Zacks 1998) was used during the dose escalation phase for dose level selection and determination of the MTD.
|
Cycle 1 (28-day treatment cycle)
|
Number of Participants DLT in Arm 2 in Dose Escalation Phase
Tidsramme: Cycle 1 (28-day treamtent cycle)
|
Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for intermittent dosing schedule (MWF weekly). A 3-parameter version of a Bayesian logistic regression model with overdose control (Babb, Rogatko, and Zacks 1998) was used during the dose escalation phase for dose level selection and determination of the MTD. |
Cycle 1 (28-day treamtent cycle)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Response as Per Investigator Assessment for Patients With Acute Myelogenous Leukemia (AML)
Tidsramme: 3.5 years
|
Response as per investigator assessment for patients include complete response, progressive disease/failure, stable disease.
|
3.5 years
|
Response as Per Investigator Assessment for Patients With Acute Myelogenous Leukemia (AML) in Expansion Phase
Tidsramme: 1.2 years
|
Stage 2 did not open for enrollment.
|
1.2 years
|
Response as Per Investigator Assessment for Patients With Hodgkin's Lymphoma (HD)
Tidsramme: 3.5 years
|
Response as per investigator assessment for patients include complete response, partial remission, stable disease, progressive disease (PD)/failure.
|
3.5 years
|
Response as Per Investigator Assessment for Patients With Myelodysplastic Syndromes (MDS)
Tidsramme: 3.5 years
|
Response as per investigator assessment for patients include complete response, stable disease, progressive disease/failure, partial remission.
|
3.5 years
|
Maximum Plasma Concentration of Panobinostat After the First Dose in Arms 1 and 2
Tidsramme: Day 1
|
Day 1
|
|
Half Life of Panobinostat After the First Dose in Arms 1 and 2
Tidsramme: Day 1
|
Day 1
|
|
Maximum Plasma Concentration of Panobinostat After Multiple Doses in Arm 1 on Day 15
Tidsramme: Day 15
|
From day 15 by dose with schedule: MWF every week
|
Day 15
|
Half Life of Panobinostat After Multiple Doses in Arm 1 on Day 15
Tidsramme: Day 15
|
Day 15
|
|
Geometric Mean Ratio (GMR) Comparing Treatment Days in Arm 1
Tidsramme: Day 15/day 1
|
MWF Every week schedule n = number of subjects with non-missing values.
|
Day 15/day 1
|
Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 1 (MWF Every Week), Group X
Tidsramme: Days 1, 5, 8, 10, 15
|
Reporting the number of patients with a reading at the timepoint in the dose group.
|
Days 1, 5, 8, 10, 15
|
Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 1 (MWF Every Week), Group Y
Tidsramme: Days 5, 8, end of study (up to 3.5 years)
|
Days 5, 8, end of study (up to 3.5 years)
|
|
Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 2 (MWF Every Other Week), Group X
Tidsramme: Days 5, 8, 10, 12, 15, End of study, Unscheduled (up to 3.5 years)
|
Days 5, 8, 10, 12, 15, End of study, Unscheduled (up to 3.5 years)
|
|
Percentage of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 2 (MWF Every Other Week), Group Y
Tidsramme: Days 5, 8, 10, 12, 15, End of study (up to 3.5 years)
|
Days 5, 8, 10, 12, 15, End of study (up to 3.5 years)
|
|
Highest Percent Change in Fetal Hemoglobin From Baseline in Arm 1 (MWF Every Week)
Tidsramme: Post dose to pre-dose (up to 3.5 years)
|
All blood samples were drawn immediately prior to each administration of LBH589 dose and at the end of treatment (≤ 7 days post last dose (preferably ≥ 4 days [96 hours]))
|
Post dose to pre-dose (up to 3.5 years)
|
Highest Percent Change of Fetal Hemoglobin From Baseline in Arm 2 (MWF Every Other Week)
Tidsramme: Post dose to pre-dose (up to 3.5 years)
|
All blood samples were drawn immediately prior to each administration of LBH589 dose and at the end of treatment (≤ 7 days post last dose (preferably ≥ 4 days [96 hours]))
|
Post dose to pre-dose (up to 3.5 years)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. marts 2003
Primær færdiggørelse (Faktiske)
3. december 2009
Studieafslutning (Faktiske)
3. december 2009
Datoer for studieregistrering
Først indsendt
12. februar 2008
Først indsendt, der opfyldte QC-kriterier
21. februar 2008
Først opslået (Skøn)
22. februar 2008
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
5. januar 2021
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
16. december 2020
Sidst verificeret
1. juli 2017
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Hjerte-kar-sygdomme
- Karsygdomme
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Neoplasmer efter sted
- Hæmatologiske sygdomme
- Hæmoragiske lidelser
- Hæmostatiske lidelser
- Paraproteinæmier
- Blodproteinforstyrrelser
- Neoplasmer, Plasmacelle
- Hæmatologiske neoplasmer
- Myelomatose
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antineoplastiske midler
- Histon deacetylase hæmmere
- Panobinostat
Andre undersøgelses-id-numre
- CLBH589B2102
- 2005-003670-26
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ja
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med LBH589
-
Sidney Kimmel Cancer Center at Thomas Jefferson...NovartisAfsluttetHjernemetastase | Tilbagevendende gliom | Meningiom af høj kvalitetForenede Stater
-
City of Hope Medical CenterNational Cancer Institute (NCI)Afsluttet
-
Mayo ClinicNational Cancer Institute (NCI)AfsluttetEkstranodal marginalzone B-celle lymfom i slimhinde-associeret lymfoidt væv | Nodal Marginal Zone B-celle lymfom | Tilbagevendende voksen Burkitt lymfom | Tilbagevendende voksent diffust storcellet lymfom | Tilbagevendende voksenlymfoblastisk lymfom | Tilbagevendende grad 1 follikulært lymfom | Tilbagevendende... og andre forholdForenede Stater
-
Abdullah KutlarSecura Bio, Inc.RekrutteringSeglcellesygdomForenede Stater
-
Mayo ClinicNational Cancer Institute (NCI)AfsluttetEkstranodal marginalzone B-celle lymfom i slimhinde-associeret lymfoidt væv | Nodal Marginal Zone B-celle lymfom | Tilbagevendende voksen Burkitt lymfom | Tilbagevendende voksent diffust storcellet lymfom | Tilbagevendende voksenlymfoblastisk lymfom | Tilbagevendende grad 1 follikulært lymfom | Tilbagevendende... og andre forholdForenede Stater
-
Anne Beaven, MDNovartisAfsluttetDiffust storcellet B-celle lymfomForenede Stater
-
Novartis PharmaceuticalsAfsluttetMetastatisk brystkræft | HER-2 positiv brystkræftBelgien, Holland, Australien, Italien, Forenede Stater
-
H. Lee Moffitt Cancer Center and Research InstituteNovartis PharmaceuticalsAfsluttetMyelomatoseForenede Stater
-
Novartis PharmaceuticalsAfsluttetMyelomatoseForenede Stater, Tyskland
-
Novartis PharmaceuticalsAfsluttetMyelodysplastiske syndromer (MDS) | Akut myeloid leukæmi (AML) | Kronisk myelomonocytisk leukæmi (CMML)Japan